The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Nov 2020 08:33

RNS Number : 0764E
Scancell Holdings Plc
03 November 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Scancell Holdings plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Redmile Group, LLC

City and country of registered office (if applicable)

San Francisco, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

RedCo I, L.P.

Redmile Biopharma Investments II, L.P.

Redmile Capital Offshore Fund (ERISA), Ltd.

Redmile Strategic Master Fund, LP

Redmile Capital Offshore II Master Fund, Ltd.

Redmile Capital Offshore Master Fund, Ltd.

Redmile Capital Fund, LP

City and country of registered office (if applicable)

San Francisco, USA

5. Date on which the threshold was crossed or reachedvi:

02/11/2020

6. Date on which issuer notified (DD/MM/YYYY):

03/11/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

29.97

N/A

29.97

791,917,828

Position of previous notification (if

applicable)

25.48

N/A

25.48

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares

GB00B63D3314

N/A

237,306,384

N/A

29.97

SUBTOTAL 8. A

237,306,384

29.97

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

RedCo I, L.P.

11.13

N/A

11.13

Redmile Biopharma Investments II, L.P.

9.11

N/A

9.11

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Redmile Group, LLC is the investment manager for: RedCo I, L.P; Redmile Biopharma Investments II, L.P.; Redmile Capital Offshore Fund (ERISA), Ltd.; Redmile Strategic Master Fund, LP; Redmile Capital Offshore II Master Fund, Ltd.; Redmile Capital Offshore Master Fund, Ltd; and Redmile Capital Fund, LP.

 

Place of completion

San Francisco, USA

Date of completion

03/11/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFIFVTLLLVIII
Date   Source Headline
18th Jan 20237:00 amRNSNotice of Interim Results
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20223:18 pmRNSResult of Annual General Meeting
7th Nov 20227:00 amRNSLicenses Vaccitech technology to advance Modi-2
31st Oct 20227:00 amRNSFirst patient dosed in expansion phase of ModiFY
28th Oct 20223:00 pmRNSNotice of AGM
28th Oct 20227:00 amRNSResults for the year ended 30 April 2022
26th Oct 20227:00 amRNSDirectorate Changes
25th Oct 20224:42 pmRNSSecond Price Monitoring Extn
25th Oct 20224:37 pmRNSPrice Monitoring Extension
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 202211:05 amRNSSecond Price Monitoring Extn
25th Oct 202211:00 amRNSPrice Monitoring Extension
25th Oct 20227:00 amRNSSigns Commercial License Agreement with Genmab
13th Oct 20227:00 amRNSChange of Nominated Adviser
28th Sep 202212:31 pmRNSHolding(s) in Company
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
23rd Sep 20227:00 amRNSPreclinical data at the EuroMAbNet Annual Meeting
6th Sep 202212:54 pmRNSChange of Registered Office
16th Aug 20222:00 pmRNSFirst patient dosed in Cohort 2 of the ModiFY
23rd Jun 20227:00 amRNSScancell to produce TCB antibodies
15th Jun 20222:06 pmRNSSecond Price Monitoring Extn
15th Jun 20222:00 pmRNSPrice Monitoring Extension
15th Jun 20227:00 amRNSPhase 2 SCOPE trial of SCIB1 vaccine expanded
13th Jun 20227:00 amRNSFirst patient dosed in Modi-1 Phase 1 trial
12th Apr 20223:47 pmRNSChange of Registered Holder of Shares
11th Apr 20222:06 pmRNSSecond Price Monitoring Extn
11th Apr 20222:00 pmRNSPrice Monitoring Extension
11th Apr 202211:05 amRNSSecond Price Monitoring Extn
11th Apr 202211:00 amRNSPrice Monitoring Extension
11th Apr 20227:00 amRNSModi-1 Phase 1/2 trial open for recruitment
29th Mar 20227:00 amRNSUpdate on COVIDITY clinical trial
17th Mar 20227:00 amRNSScancell progresses its new anti-glycan mAb
3rd Mar 20229:55 amRNSDirector Dealing
31st Jan 20227:00 amRNSUpdate on COVIDITY Phase 1 clinical trial
26th Jan 20227:00 amRNSInterim Results for the 6 months ended 31 Oct 2021
22nd Dec 20219:45 amRNSNotice of Interim Results
13th Dec 20214:41 pmRNSSecond Price Monitoring Extn
13th Dec 20214:36 pmRNSPrice Monitoring Extension
23rd Nov 20213:58 pmRNSResult of AGM
19th Nov 20217:00 amRNSFirst patient dosed in SCIB1 Phase 2 trial
3rd Nov 202110:28 amRNSDirector Dealing
2nd Nov 202110:07 amRNSDirector Dealing
1st Nov 20219:50 amRNSNotice of Annual General Meeting
29th Oct 20217:00 amRNSResults for the year ended 30 April 2021
28th Oct 202111:23 amRNSExtension of CLN Redemption Dates
19th Oct 20217:00 amRNSNew facilities at The Oxford Science Park
15th Oct 20217:00 amRNSNotice of Final Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.